Manager Forward Deployed Engineer - Software Engineering
About the job
- A bachelor's degree in Computer Science, Engineering, Information Technology, Software Engineering, or a related field is required; a master's degree is preferred.
- At least 10 years of experience in software engineering, full stack development, enterprise application delivery, or digital product engineering.
- At least 5 years of people leadership experience managing engineering teams, technical leads, or distributed delivery teams.
- Proven experience delivering enterprise-scale applications using modern front-end, back-end, API, and cloud technologies.
- Experience implementing Agile, DevSecOps, continuous integration and continuous delivery, automated testing, and production support practices.
- Experience working with global stakeholders and cross-functional technology teams in a matrixed organization.
- Technical proficiency with React, Angular, or modern JavaScript frameworks; TypeScript or JavaScript; HTML5 and CSS3; responsive design; accessibility and UX collaboration; Java, .NET, Node.js, or Python; REST APIs and microservices; API security and authentication; relational and NoSQL databases; event-driven integrations; Azure or AWS; containers and Kubernetes; continuous integration and continuous delivery pipelines; Infrastructure as Code; monitoring, logging, and observability; secure software development lifecycle; automated testing; code quality and reviews; Agile delivery; architecture and design patterns; and production support.
- Required Skills list: Analytical Reasoning, Consulting, Cost Management, Developing Others, Human-Computer Interaction, Inclusive Leadership, Leadership, People Performance Management, Performance Measurement, Product Development, Product Strategies, Project Management Methodology, Research and Development, Resource Management, Software Development Management, Strategic Supply Chain Management, and Team Management.
- Lead, mentor, and develop a high-performing team of full stack engineers, technical leads, and application developers.
- Set engineering standards for secure coding, architecture, code quality, testing, observability, and production readiness.
- Drive technical excellence through design reviews, code reviews, reusable patterns, and engineering communities of practice.
- Build a culture of ownership, innovation, inclusion, continuous improvement, and accountability.
- Lead development of modern web applications, APIs, services, dashboards, portals, workflow applications, and digital products.
- Guide architecture and implementation across front-end, back-end, integration, database, authentication, and deployment layers.
- Ensure solutions are scalable, maintainable, secure, accessible, performant, and aligned with enterprise technology standards.
- Partner with Product Management and UX teams to translate user needs into intuitive, reliable, and valuable digital experiences.
- Drive adoption of cloud-native design patterns, microservices, API-first architecture, containerization, and managed cloud services.
- Collaborate with enterprise architecture and platform engineering teams to define reusable application patterns and reference architectures.
- Ensure effective use of cloud capabilities for resiliency, monitoring, cost optimization, automation, and scalability.
- Support modernization of legacy applications into modern, modular, and cloud-ready technology platforms.
- Implement continuous integration and continuous delivery pipelines, automated testing, quality gates, security scans, infrastructure automation, and release management practices.
- Establish operational key performance indicators covering reliability, performance, deployment frequency, incident trends, and service health.
- Partner with cybersecurity, privacy, and quality teams to ensure secure software development lifecycle practices.
- Drive root cause analysis, technical debt reduction, application rationalization, and continuous platform improvement.
- Lead Agile delivery teams using Product Operating Model principles and outcome-focused execution.
- Collaborate with business stakeholders, product owners, architects, data teams, AI teams, testing teams, and vendor partners.
- Create delivery roadmaps, manage dependencies, mitigate risks, and communicate progress to senior stakeholders.
- Balance speed, quality, compliance, user needs, and long-term sustainability in technology decisions.
- Ensure applications comply with applicable enterprise security, privacy, quality, accessibility, and regulatory requirements.
- Support delivery practices aligned with GxP, Computer System Validation, GDPR, HIPAA, and internal Johnson & Johnson technology standards where applicable.
- Maintain audit-ready engineering documentation, traceability, and release evidence for regulated applications.
- Promote responsible use of data and AI-enabled capabilities within application experiences.
- Experience in Pharmaceutical, Healthcare, Life Sciences, or other regulated industries.
- Experience leading teams that build applications for Clinical Development, R&D, Medical Affairs, Regulatory, or enterprise data platforms.
- Experience integrating digital applications with data platforms, analytics, AI services, workflow tools, and enterprise identity platforms.
- Experience with Product Operating Model, platform thinking, reusable engineering assets, and product-based delivery.
- Relevant certifications in Azure, AWS, software architecture, Agile, DevOps, cybersecurity, or application engineering.
- Strong executive interpersonal skills and the ability to simplify sophisticated technology topics for business stakeholders.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
- TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
- CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.
What critics are saying
- Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
- Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
- AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.
What makes Johnson & Johnson unique
- J&J has 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
- CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.